Plasma lipoproteome
The objective of this study is to provide initial proof-of-concept that the plasma lipoproteome more likely differ between AD cases and controls when measured in individual plasma lipoprotein fractions than when measured as total in immunodepleted plasma.
People with AD
5 AD cases and 5 sex- and age-matched controls
blood draw, mild discomfort, in clinic visits
phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, western blot, or qPCR)
Department of Laboratory Medicine and Pathology, University of Minnesota; Masonic Cancer Center, University of Minnesota; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota; Department of Biostatistics, University of Minnesota;Department of Experimental and Clinical Pharmacology, University of Minnesota;School of Nursing, University of Minnesota
Li, D., Huang, F., Zhao, Y., Villata, P. W., Griffin, T. J., Zhang, L., ... & Yu, F. (2018). Plasma lipoproteome in Alzheimer’s disease: a proof-of-concept study. Clinical Proteomics, 15(1), 31. https://www.ncbi.nlm.nih.gov/pubmed/30250409